Bristol-Myers Squibb Company (BMY) & AstraZeneca PLC (AZN) Release: Pooled Analysis Showed Onglyza® (saxagliptin) Provided Improvements in Key Measures of Blood Sugar Control in Adults With Type 2 Diabetes at High Risk for CV Disease
7/30/2012 12:20:29 PM
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the results of analyses showing that Onglyza®(saxagliptin) 5 mg demonstrated improvements across key measures of blood sugar control (glycosylated hemoglobin levels, or HbA1c; fasting plasma glucose, or FPG and post-prandial glucose, or PPG) compared to placebo in adult patients with type 2 diabetes at high risk for cardiovascular disease. These results were from a pooled, post-hoc assessment of five, 24-week, Phase III studies encompassing 1,681 patients with type 2 diabetes and varying degrees of cardiovascular risk, characterized by the presence of known risk factors or a history of cardiovascular disease. Adverse events, serious adverse events, death, discontinuation and hypoglycemia were also evaluated by various patient sub-groups. The data were presented today in two oral presentations at the 17th World Congress on Heart Disease in Toronto, Canada.